Background Introduction

In biomedical research, antibodies serve as indispensable tools. However, the absence of standardized methods for evaluating antibody performance has left researchers without reliable guidelines for antibody selection. The vast diversity and inconsistent quality of commercially available antibodies not only complicate research but also drive-up costs, resulting in wasted resources and contributing to the "reproducibility crisis" in the life sciences.

Furthermore, the absence of transparent and open data-sharing mechanisms has hindered collaboration between industry and academia in identifying specific human protein antibodies. To address these challenges—standardizing antibody performance evaluation and fostering transparency and resource sharing—the "Open Science Antibody Characterization" organization (YCharOS) was established.

ABclonal Contributes to the Development of Antibody Characterization Standards

Since its inception in 2011, ABclonal has upheld stringent standards in the research, development, and production of high-quality antibodies, continuously striving for excellence. From 2023 to 2024, Dr. Hai Wu, Head of the Immunology Division at ABclonal, was honored to participate in discussions and contribute to the development of antibody characterization standards spearheaded by the YCharOS organization.

In this significant international collaboration, Dr. Hai Wu engaged in in-depth discussions with leading enterprises and experts in the research antibody field. Ultimately, they successfully established a preliminary unified standard for research antibody characterization. 

This set of characterization standards provides a vital reference for global antibody development, production, and quality evaluation. It represents a consensus in a critical area of the industry, offering lasting guidelines for the standardized development of the research antibody sector.

What Kind of Antibody Characterization Platform is YCharOS?

YCharOS is an antibody characterization platform based on gene knockout (KO) cell lines, collaboratively developed by industry and academia. It aims to systematically compare antibody performance in applications such as Western Blot (WB), Immunoprecipitation (IP), and Immunofluorescence (IF).

The platform utilizes scalable, low-resource-demand protocols, including the identification of cell lines suitable for antibody characterization, development of homologous KO controls, and standardized antibody characterization workflows. Through transparent data sharing, YCharOS facilitates the research community's identification of specific antibodies targeting human proteins, addressing challenges in resource validation and data reproducibility, and providing standardized support for scientific research.

How Does the YCharOS Platform Ensure the Reliability of Antibody Characterization?

YCharOS Antibody Selection Consensus

Meeting the Urgent Needs of Scientists is ABclonal's Ultimate Goal!

World-Leading Recombinant Rabbit Monoclonal Antibody Development Platform

ABclonal proudly operates a globally leading recombinant rabbit monoclonal antibody development platform, independently developed with proprietary intellectual property rights: the SMab^TM Platform. This platform integrates innovative workflows, including positive single B cell sorting, enrichment, bioinformatics, and recombinant monoclonal antibody expression, enabling the direct generation of ideal rabbit monoclonal antibodies from B cells.

Compared to traditional technologies, this advanced platform offers superior capabilities by providing a greater number of candidate clones, optimized through in-house bioinformatics. Its next-generation gene synthesis solutions reduce the cost of antibody engineering and expression, and the XPromoter 2.0 system ensures high-level recombinant antibody expression. Rabbit monoclonal antibodies developed on this platform feature the following key advantages:

• High specificity
• Ultra-sensitivity
• Outstanding Lot-to-Lot consistency
• High dilution capability
• Extensive application clone selection
• Flexible options for labeling and engineering modifications
  
                    
  

Click to learn more about SMab^TM Recombinant Rabbit Monoclonal Antibodies.

Since 2021, ABclonal has spearheaded the "Ten-Thousand Antibody Project," a groundbreaking initiative focused on recombinant rabbit monoclonal antibodies. Over the years, this project has steadily progressed, resulting in the successful development of more than 5,000 recombinant rabbit monoclonal antibodies to date.

Our monoclonal antibodies are meticulously selected and validated according to the stringent standards. These antibodies provide the following advantages for your research or project:

Reliable Experimental Outcomes: Success Every Time

• High specificity: Over 500 antibodies validated using gene knockout (KO) models and more than 200 confirmed via gene knockdown (KD) studies.
• Broad and extensive application validation to support fundamental research needs, including WB, IP, and IF.
• Ultra-sensitivity

Reproducible Results: Consistency for Long-term Projects

• High Lot-to-Lot consistency with minimal variation.
• Guaranteed long-term local supply, scalable production capacity, ample stock availability, and short lead times.

ABclonal Antibodies Tested and Validated Through YCharOS's Rigorous Processes (Partial List)